Compound Reviews
Retatrutide vs Tirzepatide vs Semaglutide: A Receptor-Level Comparison
One receptor, two receptors, or three. A structural and pharmacological comparison of the three most-studied incretin analogues.
August 10, 2026 · 8 min read · Novanta Research
The short version
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Retatrutide adds glucagon receptor activity, making it a triple agonist. Everything else about how they are compared follows from that difference in receptor coverage.
- Semaglutide — GLP-1 receptor only
- Tirzepatide — GIP + GLP-1 receptors
- Retatrutide — GIP + GLP-1 + glucagon receptors
Structural differences
Semaglutide is built on the native GLP-1 backbone with a substitution that blocks DPP-4 cleavage and a C18 fatty diacid chain for albumin binding. Tirzepatide is based on the GIP sequence rather than GLP-1, with its own fatty acid modification, which is why it engages both receptors.
Retatrutide is a further-engineered single chain designed to hold meaningful potency at all three receptors simultaneously. In each case the lipidation is what produces a once-weekly duration profile in published work.
Why the glucagon receptor changes the picture
Glucagon receptor activity is the conceptually interesting part of a triple agonist. Glucagon signalling raises hepatic glucose output and energy expenditure, which historically made it an unwanted target in this class.
The design premise of a triple agonist is that adding an energy-expenditure component alongside strong appetite-axis coverage produces a different overall profile than incretin activity alone. The published research on this remains an active area rather than a settled question.
What the comparison does not tell you
Receptor coverage does not translate directly into a ranking. Potency at each receptor, the balance between them, exposure over time, and study population all shape reported outcomes, and cross-trial comparisons are notoriously unreliable.
For laboratory work the practical implications are simpler: these are three distinct molecules with distinct molecular weights, distinct reconstitution volumes and distinct stability profiles. Treat them as separate compounds, not as versions of one another.
Handling notes
All three are supplied lyophilized and reconstituted with bacteriostatic water. Use the Novanta reconstitution calculator to convert vial strength and diluent volume into exact concentration before any protocol work, and store reconstituted material cold and shielded from light.
Frequently asked
- Which compound is strongest?
- Potency depends on which receptor you measure, so there is no single ranking. Retatrutide covers the most receptors, but that describes breadth of target engagement rather than a simple strength ordering.
- Are these interchangeable in a protocol?
- No. They differ in molecular weight, receptor coverage and duration, so vial strength, reconstitution volume and timing all have to be recalculated per compound.
Keep reading
For laboratory and research use only. Not for human or veterinary consumption. Novanta Research is not a compounding pharmacy and nothing in this article is medical advice or a claim that any compound diagnoses, treats, cures or prevents any condition.